Networks and Collaborations

Showing results filtered by:

The ACTG established and supports the largest Network of expert clinical and translational investigators and therapeutic clinical trials units in the world, including sites in resource-limited countries. These investigators and units serve as the major resource for HIV/AIDS research, treatment, care, and training/education in their communities.

CHAVI-ID are two consortiums established by NIAID to undertake the immunologic research required to tackle the major scientific obstacles in the development of an effective HIV vaccine. The two seven-year awards were made in 2012, one to Duke University and a second to The Scripps Research Institute.

The Centers for AIDS Research (CFAR) program at the National Institutes of Health provides administrative and shared research support to synergistically enhance and coordinate high quality AIDS research projects. CFARs accomplish this through core facilities that provide expertise, resources, and services not otherwise readily obtained through more traditional funding mechanisms.

Community Partners (CP) works to promote effective representation of the many US-based and international communities in which the NIH-funded HIV Clinical Trials Networks conduct research.

The purpose of the Creative and Novel Ideas in Research (CNIHR) Program is to create a mechanism via the established Centers for AIDS Research (CFARs) to fund developmental projects to bring insight and new ideas from early-stage investigators, some of whom will have expertise in other disciplines, to the HIV/AIDS field of study.

The Division of AIDS (DAIDS) maintains contracts that can potentially provide limited pre-clinical services including manufacturing, analytical chemistry, preclinical pharmacology and toxicology resources to investigators who are working on the development of therapeutics targeting HIV/AIDS and AIDS-related opportunistic infections, including TB.

An effective and widely available vaccine will be central to any global strategy to slow and end the HIV pandemic.

The HIV Prevention Trials Network develops and tests the safety and efficacy of primarily non-vaccine interventions designed to prevent the transmission of HIV.

The HIV Vaccine Trials Network (HVTN) is the world’s largest publicly-funded international collaboration focused on the development of vaccines to prevent HIV/AIDS.

The NIAID HIV/AIDS Clinical Trials Networks have been designed to address NIAID’s five HIV/AIDS scientific priorities.

The Networks inlcude:

The IeDEA Cohort Consortium collaborates to collect and define key variables, harmonize data, and implement methodology to effectively pool data as a cost-effective means of generating large data sets.

The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network is a global collaboration of investigators, institutions, community representatives and other partners organized for the purpose of evaluating interventions to treat and prevent HIV infection and its consequences in infants, children, adolescents, and pregnant/postpartum women through the conduct of high qual

The Microbicide Trials Network (MTN) is an NIAID-funded worldwide collaborative clinical trials network focused on preventing the sexual transmission of HIV.

The Multicenter AIDS Cohort Study (MACS) is an ongoing prospective study of the natural and treated histories of HIV-1 infection in homosexual and bisexual men conducted by sites located in Baltimore, Chicago, Pittsburgh and Los Angeles. Biological and behavioral data are collected every six months from study participants.

The Division of AIDS (DAIDS) supports a number of programs, networks, and studies to increase basic knowledge of the pathogenesis and transmission of HIV, promote the development of therapies for HIV infection and its complications and co-infections, and encourage the development of vaccines and other prevention strategies.

The Pox-Protein Public Private Partnership (P5) – comprised of the Bill & Melinda Gates Foundation, the National Institutes of Health, Sanofi Pasteur, GlaxoSmithKline (GSK), the South African Medical Research Council, the HIV Vaccine Trials Network (HVTN), and the US Military HIV Research Program – is a diverse group of organizations committed to building upon the modest protective efficacy

The U.S. Military HIV Research Program (MHRP) was established in 1985 to protect U.S. troops entering endemic HIV areas and is dedicated to HIV vaccine development, prevention, disease surveillance, and HIV care and treatment. NIAID plans and executes HIV/AIDS research projects annually with MHRP through an interagency agreement on HIV vaccine research.

PEPFAR is the U.S. government initiative to help save the lives of those living with and affected by HIV/AIDS around the world. This historic commitment is the largest by any nation to combat a single disease internationally, and PEPFAR investments also help alleviate suffering from other diseases across the global health spectrum.

The Women's Interagency HIV Study (WIHS), established in 1993, is a multi-center, prospective, observational cohort study of women living in the United States who are either HIV-infected or at risk for HIV acquisition.  WIHS plays an important role in NIAID’s effort to understand the current epidemiology of HIV infection, disease progression, treatment use and outcomes, and related co-morbiditi